BUCKINGHAMSHIRE, United Kingdom--(BUSINESS WIRE)--Lumendi Ltd., a privately held innovative medical device company, announced today that Chief Executive Officer Peter Johann, Ph.D., is scheduled to present at the Digital Medicine & Medtech Showcase on Wednesday, January 10, 2018 at 1:15 p.m. (PST) in Track A-Cyril Magnin II on the 4th floor. The conference is being held January 8-10, 2018 at the hotel Parc 55 San Francisco.
Lumendi is dedicated to improving healthcare through the development and application of medical technology that reduces the number of surgical colon intervention and procedure time in endoscopic procedures, positively impacts recovery rates and outcomes, and decreases costs to the healthcare system. Lumendi’s DiLumen™ EIP device, FDA cleared and commercially available, was developed through collaboration between Lumendi Ltd and the Minimally Invasive Technologies program (MINT) at Weill Cornell Medical Center and New York-Presbyterian Hospital. When used as directed, DiLumen EIP creates an isolated, stabilized Therapeutic Zone™ (TZ) within the intestine that straightens the target area and flattens the folds so clinicians can see and treat isolated segments of the bowel. Additional devices are under development, several of which were submitted in November 2017 for regulatory clearance by the FDA.
About Lumendi, Ltd (http://www.lumendi.com) is a privately held innovative, medical device company headquartered in Buckinghamshire, UK. Lumendi is focused on developing, marketing and distributing surgical tools and devices that provide safe, cost-effective solutions for minimally invasive gastrointestinal interventions. Lumendi Ltd. holds a worldwide exclusive license from Cornell University on the DiLumen™ technology. Lumendi LLC, headquartered in Westport, CT is a wholly owned subsidiary of Lumendi, Ltd.
|
Follow us on |
|||
| YouTube | |||
